Abbott Laboratories's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 26 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 136.32.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
Abbott Laboratories is an American multinational health care and medical devices corporation headquartered in Abbott Park, Illinois. Founded in 1888 by Chicago physician Wallace Calvin Abbott, the company initially focused on formulating known drugs. Today, it offers medical devices, diagnostics, branded generic medications, and nutritional products. In 2013, Abbott separated its research-based pharmaceuticals division into AbbVie.
Abbott's product lineup includes Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip.
The current financial score of Abbott Laboratories is 9.05, ranking 19 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 11.46B, representing a year-over-year increase of 4.42%, while its net profit experienced a year-over-year increase of 80.76%.
Key Metrics
The current valuation score of Abbott Laboratories is 6.40, ranking 162 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 28.44, which is 36.07% below the recent high of 38.70 and 49.28% above the recent low of 14.42.
The current earnings forecast score of Abbott Laboratories is 7.94, ranking 106 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 145.00, with a high of 162.00 and a low of 122.34.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Abbott Laboratories is 6.68, ranking 102 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 121.94 and the support level at 97.75, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Abbott Laboratories is 7.00, ranking 82 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 81.82%, representing a quarter-over-quarter decrease of 0.06%. The largest institutional shareholder is The Vanguard, holding a total of 174.89M shares, representing 10.06% of shares outstanding, with 3.50% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Abbott Laboratories is 9.59, ranking 5 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.75. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
